Pharma Blog Watch

Third Strike for Corlux (Clinical Psychology and Psychiatry)
"The interesting thing about Corlux (mifepristone/RU-486) is that no matter how it fares in clinical trials, it is always a winner," this blogger writes. "In the latest trial, Corlux was again not effective on the primary outcome measure, which assessed the psychotic symptoms of psychotic depression."

"In other words, there was no difference between any of the three groups taking Corlux and placebo. None," the blogger continues. "So it appears that [Corcept Therapeutics] started data dredging (e.g., running a bunch of statistical tests until they found one that yielded positive results) and found that there was a correlation between plasma concentration of drug and clinical response."